Anil K. Sood - Publications

Affiliations: 
The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Cell Biology, Molecular Biology, Oncology

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, ... ... Sood AK, et al. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers. 14. PMID 35326647 DOI: 10.3390/cancers14061496  0.362
2022 Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. Journal of Cancer Research and Clinical Oncology. PMID 35094142 DOI: 10.1007/s00432-021-03885-z  0.308
2021 Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, ... ... Sood AK, et al. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine. PMID 34799731 DOI: 10.1038/s41591-021-01566-5  0.657
2021 Sasano T, Gonzalez-Delgado R, Muñoz NM, Carlos-Alcade W, Cho MS, Sheth RA, Sood AK, Afshar-Kharghan V. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. Journal of Thrombosis and Haemostasis : Jth. PMID 34608736 DOI: 10.1111/jth.15544  0.355
2021 Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis. 10: 65. PMID 34588424 DOI: 10.1038/s41389-021-00349-4  0.303
2021 Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim MS, Umamaheswaran S, Glassman D, Wen Y, ... ... Sood AK, et al. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Molecular Cancer Therapeutics. PMID 34583979 DOI: 10.1158/1535-7163.MCT-21-0370  0.316
2021 Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology. PMID 34476576 DOI: 10.1007/s00432-021-03778-1  0.334
2021 Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. PMID 34433970 DOI: 10.1038/s41586-021-03664-3  0.307
2021 Lutgendorf SK, Ramirez E, Schrepf A, Valentine MC, Charlton M, Zimmerman MB, Goodheart MJ, Zia S, Sood AK, Thaker PH. Rural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecologic Oncology. PMID 34400004 DOI: 10.1016/j.ygyno.2021.07.035  0.305
2021 Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AK. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecologic Oncology. PMID 34391578 DOI: 10.1016/j.ygyno.2021.08.003  0.344
2021 Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, ... ... Sood AK, et al. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4454. PMID 34341059 DOI: 10.1158/1078-0432.CCR-21-2120  0.594
2021 Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, ... Sood AK, et al. Editor's Note: Functional Roles of and in Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4452. PMID 34341057 DOI: 10.1158/1078-0432.CCR-21-2118  0.576
2021 Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MMK, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, ... ... Sood AK, et al. Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4450. PMID 34341055 DOI: 10.1158/1078-0432.CCR-21-2116  0.59
2021 Saha B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Bao G, Jain A. Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Science Advances. 7. PMID 34290095 DOI: 10.1126/sciadv.abg5283  0.364
2021 Cuneo MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SK. Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. Psychosomatic Medicine. 83: 417-422. PMID 34080583 DOI: 10.1097/PSY.0000000000000935  0.346
2021 Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, Köbel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, et al. Joint IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research. Carcinogenesis. PMID 34037709 DOI: 10.1093/carcin/bgab043  0.347
2021 Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Cheng W, Sood AK, Liu J, Gan B. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. PMID 33927351 DOI: 10.1038/s41388-021-01790-w  0.33
2021 Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology. PMID 33867146 DOI: 10.1016/j.ygyno.2021.04.012  0.328
2021 Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecologic Oncology. PMID 33838925 DOI: 10.1016/j.ygyno.2021.04.002  0.341
2021 Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Sood AK, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 6. PMID 33793425 DOI: 10.1172/jci.insight.149895  0.544
2021 Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. 131. PMID 33792569 DOI: 10.1172/JCI149893  0.323
2021 Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, ... ... Sood AK, et al. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecologic Oncology. PMID 33563487 DOI: 10.1016/j.ygyno.2020.12.010  0.341
2021 Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers. 13. PMID 33562443 DOI: 10.3390/cancers13040626  0.342
2021 Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, ... ... Sood AK, et al. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology. PMID 33551196 DOI: 10.1016/j.ygyno.2021.01.022  0.305
2021 Karakuzu O, Tsimberidou AM, Holley VR, Adat A, Patel SP, Sood AK, Conley AP, Urschel GE, Healey DI, O'Neill V, Janku F. Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study. Journal of Clinical Oncology. 39: 2558-2558. DOI: 10.1200/JCO.2021.39.15_SUPPL.2558  0.323
2021 Handley K, Sims T, Glassman D, Fleming N, Lee S, Fellman B, Yao H, Yao J, Liu J, Bast R, Lu Z, Westin S, Rangel K, Celestino J, Bateman N, ... ... Sood A, et al. If looks could kill: morphologic subtypes of high-grade serous ovarian cancer Gynecologic Oncology. 162: S20-S21. DOI: 10.1016/s0090-8258(21)00685-5  0.36
2020 Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, ... Sood AK, et al. Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 33262282 DOI: 10.1073/pnas.2013595117  0.401
2020 Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology. PMID 33196436 DOI: 10.1016/j.ygyno.2020.10.027  0.364
2020 Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, ... ... Sood AK, et al. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 33154095 DOI: 10.1136/ijgc-2020-001718  0.311
2020 Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. PMID 33149280 DOI: 10.1038/s41388-020-01517-3  0.414
2020 Kaur B, Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Karuppaiyah S, Pei G, Zhao Z, Yoo JY. Oncolytic HSV therapy modulates vesicular trafficking inducing cisplatin sensitivity and anti-tumor immunity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33087329 DOI: 10.1158/1078-0432.CCR-20-2210  0.302
2020 Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. Molecular Cancer Therapeutics. PMID 32943548 DOI: 10.1158/1535-7163.Mct-20-0030  0.374
2020 Cata JP, Sood AK, Eltzschig HK. Anesthetic Drugs and Cancer Progression: Fact or Fiction. Anesthesiology. PMID 32833387 DOI: 10.1097/Aln.0000000000003510  0.392
2020 Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 11: 2819-2833. PMID 32754300 DOI: 10.18632/Oncotarget.27667  0.445
2020 Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly K, Sood AK. Blockade of the short-form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer. Molecular Cancer Therapeutics. PMID 32737156 DOI: 10.1158/1535-7163.Mct-19-1026  0.521
2020 Saha B, Mathur T, Handley KF, Hu W, Afshar-Kharghan V, Sood AK, Jain A. OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Advances. 4: 3329-3342. PMID 32717032 DOI: 10.1182/Bloodadvances.2020001632  0.426
2020 Lutgendorf SK, Penedo F, Goodheart MJ, Dahmoush L, Arevalo JMG, Thaker PH, Slavich GM, Sood AK, Cole SW. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer. PMID 32691853 DOI: 10.1002/Cncr.33060  0.386
2020 Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, ... ... Sood AK, et al. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. Iscience. 23: 101289. PMID 32623336 DOI: 10.1016/J.Isci.2020.101289  0.485
2020 Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, Wright JD. Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. Jama Oncology. PMID 32525512 DOI: 10.1001/Jamaoncol.2020.1702  0.374
2020 Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors. Molecular Cancer Therapeutics. PMID 32499298 DOI: 10.1158/1535-7163.Mct-19-0977  0.467
2020 Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, ... ... Sood AK, et al. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications. 11: 2867. PMID 32493919 DOI: 10.1038/S41467-020-16661-3  0.58
2020 Maoz A, Matsuo K, Ciccone MA, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. Cancers. 12. PMID 32485873 DOI: 10.3390/Cancers12061398  0.427
2020 Matsuo K, Chang EJ, Matsuzaki S, Mandelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, Wright JD. Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. Gynecologic Oncology. PMID 32402635 DOI: 10.1016/J.Ygyno.2020.04.045  0.351
2020 Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, ... ... Sood AK, et al. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports. 31: 107502. PMID 32294438 DOI: 10.1016/J.Celrep.2020.03.066  0.396
2020 Wi TI, Byeon Y, Won JE, Lee JM, Kang TH, Lee JW, Lee YJ, Sood AK, Han HD, Park YM. Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy. Journal of Biomedical Nanotechnology. 16: 201-211. PMID 32252881 DOI: 10.1166/Jbn.2020.2883  0.334
2020 Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Felllman BM, Jimenez C, Schmeler KM. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. PMID 32125711 DOI: 10.1002/Cncr.32807  0.303
2020 Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, et al. Induction of antitumor immunity in mice by the combination of nanoparticle-based Photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine : Nanotechnology, Biology, and Medicine. 102169. PMID 32059873 DOI: 10.1016/J.Nano.2020.102169  0.334
2020 Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecologic Oncology. PMID 32037195 DOI: 10.1016/J.Ygyno.2020.01.042  0.391
2020 Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, ... ... Sood AK, et al. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. Ebiomedicine. 52: 102630. PMID 31972470 DOI: 10.1016/J.Ebiom.2020.102630  0.349
2020 Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, et al. Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology. PMID 31969252 DOI: 10.1016/J.Ygyno.2019.12.033  0.351
2020 Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Scientific Reports. 10: 520. PMID 31949258 DOI: 10.1038/S41598-020-57477-X  0.416
2020 El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling. 109539. PMID 31935430 DOI: 10.1016/J.Cellsig.2020.109539  0.497
2020 Stur E, Molin GZD, Wu S, Baggerly K, Tworoger S, Levine D, Karlan B, Moore K, Lutgendorf S, Sood A. Abstract A26: Molecular analysis of short- vs. long-term ovarian cancer survivors Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-A26  0.472
2020 Niu N, Li X, Yao J, Sood A, Liu J. Abstract A17: Polyploid giant cancer cells lead to evolution of drug resistance in high-grade ovarian cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A17  0.425
2020 Westin SN, Lee S, Zhao L, Yuan Y, Wu J, Hajek R, Sharafi S, Meyer LA, Fleming ND, Jazaeri A, Coleman RL, Lu KH, Mills GB, Zhang J, Futreal A, ... Sood AK, et al. Abstract CT188: Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct188  0.367
2020 Naing A, Karp D, Piha-Paul SA, Pant S, Subbiah V, Bodurka DC, Fu S, Jazaeri AA, Kato S, Schmeler K, Nick A, Yang Y, Akhmedzhanov FO, Fessahaye S, Gong J, ... ... Sood AK, et al. Abstract CT163: Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct163  0.394
2020 Ma S, Mangala LS, Hu W, Bayaktar E, Hu W, Jennings NB, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 6331: Cloaking VEGF in small extracellular vesicles as a cause of adaptive resistance to anti-VEGF therapy Cancer Research. 80: 6331-6331. DOI: 10.1158/1538-7445.Am2020-6331  0.389
2020 Umamaheswaran S, Dasari SK, Yokoi A, Stur E, Sood AK. Abstract 6202: Effect of sympathetic nervous system mediators on the tumor microenvironment via small extracellular vesicles in ovarian cancer Cancer Research. 80: 6202-6202. DOI: 10.1158/1538-7445.Am2020-6202  0.46
2019 Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecologic Oncology. PMID 31954535 DOI: 10.1016/J.Ygyno.2019.08.030  0.484
2019 Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD. Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology. PMID 31954534 DOI: 10.1016/J.Ygyno.2019.11.122  0.414
2019 Seiler A, Sood AK, Jenewein J, Fagundes CP. Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. Brain, Behavior, and Immunity. PMID 31881262 DOI: 10.1016/J.Bbi.2019.12.013  0.386
2019 Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, ... ... Sood AK, et al. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Reports. 29: 4389-4406.e10. PMID 31875548 DOI: 10.1016/J.Celrep.2019.11.085  0.409
2019 Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. Rna Biology. 1-12. PMID 31847695 DOI: 10.1080/15476286.2019.1702283  0.44
2019 Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS. Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecologic Oncology. PMID 31839342 DOI: 10.1016/J.Ygyno.2019.12.011  0.397
2019 Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK. Mechanisms of nuclear content loading to exosomes. Science Advances. 5: eaax8849. PMID 31799396 DOI: 10.1126/Sciadv.Aax8849  0.395
2019 Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, ... ... Sood AK, et al. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports. 9: 17589. PMID 31772388 DOI: 10.1038/S41598-019-53872-1  0.372
2019 Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, ... ... Sood AK, et al. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology. 20: 253. PMID 31771620 DOI: 10.1186/S13059-019-1848-3  0.417
2019 Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz M. Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstetrics and Gynecology. 134: 1253-1259. PMID 31764736 DOI: 10.1097/Aog.0000000000003579  0.301
2019 Lara OD, Wang Y, Asare A, Xu T, Chiu HS, Liu Y, Hu W, Sumazin P, Uppal S, Zhang L, Rauh-Hain JA, Sood AK. Pan-cancer clinical and molecular analysis of racial disparities. Cancer. PMID 31730714 DOI: 10.1002/Cncr.32598  0.383
2019 Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. The Journal of Clinical Investigation. PMID 31682236 DOI: 10.1172/Jci123396  0.384
2019 Handley KF, Sood AK. A solution to the dilution: The role for biomarkers in advanced ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31672769 DOI: 10.1158/1078-0432.Ccr-19-3072  0.331
2019 Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK. Clinical and biological significance of expression in endometrial cancer. Cancer Biology & Therapy. 1-10. PMID 31640461 DOI: 10.1080/15384047.2019.1672455  0.5
2019 Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, Tworoger SS. Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study. Psychosomatic Medicine. PMID 31592935 DOI: 10.1097/Psy.0000000000000747  0.394
2019 Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C. Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjugate Chemistry. PMID 31560538 DOI: 10.1021/Acs.Bioconjchem.9B00587  0.34
2019 Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, ... ... Sood AK, et al. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31391192 DOI: 10.1158/1078-0432.Ccr-18-3448  0.46
2019 Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, ... ... Sood AK, et al. Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Scientific Reports. 9: 11153. PMID 31371750 DOI: 10.1038/S41598-019-47578-7  0.366
2019 Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park, N.Y.). 33. PMID 31365748  0.364
2019 Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, ... Sood AK, et al. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecologic Oncology. PMID 31353053 DOI: 10.1016/J.Ygyno.2019.07.004  0.436
2019 Bach DH, Zhang W, Sood AK. Chromosomal Instability in Tumor Initiation and Development. Cancer Research. PMID 31350294 DOI: 10.1158/0008-5472.Can-18-3235  0.4
2019 Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, ... ... Sood AK, et al. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. PMID 31289363 DOI: 10.1038/S41388-019-0862-Y  0.385
2019 Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, et al. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 10: 3533-3546. PMID 31191824 DOI: 10.18632/Oncotarget.26947  0.303
2019 Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31126961 DOI: 10.1158/1078-0432.Ccr-19-0619  0.414
2019 Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. PMID 31063534 DOI: 10.1093/Carcin/Bgz062  0.331
2019 Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, ... Sood AK, et al. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. PMID 31012964 DOI: 10.1002/Cncr.32053  0.392
2019 Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology. 106: 244-251. PMID 31005045 DOI: 10.1016/J.Psyneuen.2019.04.007  0.501
2019 Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, ... Sood AK, et al. GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition. Molecular Cancer Therapeutics. PMID 30926640 DOI: 10.1158/1535-7163.Mct-18-0770  0.456
2019 Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, et al. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. PMID 30918328 DOI: 10.1038/S41388-019-0786-6  0.439
2019 Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Molecular Therapy. Nucleic Acids. 16: 118-129. PMID 30861414 DOI: 10.1016/J.Omtn.2019.02.005  0.385
2019 Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004  0.466
2019 Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecologic Oncology. PMID 30797590 DOI: 10.1016/J.Ygyno.2019.02.003  0.462
2019 Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clinical Chemistry. PMID 30770374 DOI: 10.1373/Clinchem.2018.299289  0.388
2019 Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, ... ... Sood AK, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Ebiomedicine. PMID 30655206 DOI: 10.1016/J.Ebiom.2018.11.045  0.425
2019 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. The Lancet. Oncology. 20: e15-e28. PMID 30614472 DOI: 10.1016/S1470-2045(18)30786-1  0.384
2019 Fleming ND, Westin SN, Meyer L, Rauh-Hain JA, Shafer A, Onstad M, Cobb LP, Bevers MW, Burzawa JK, Zand B, Fellman BM, Jazaeri AA, Levenback CF, Coleman RL, Soliman PT, ... Sood AK, et al. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer. Journal of Clinical Oncology. 37: 5570-5570. DOI: 10.1200/Jco.2019.37.15_Suppl.5570  0.392
2019 Harrison R, Cantor SB, Villanueva M, Suidan RS, Sun CC, Rauh-Hain JA, Westin SN, Fleming ND, Sood AK, Lu KH, Meyer L. Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer. Journal of Clinical Oncology. 37: 5556-5556. DOI: 10.1200/Jco.2019.37.15_Suppl.5556  0.375
2019 Shuford S, Elder J, Puls L, Weroha J, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell L, Conrads T, Corless C, Sood AK, Gevaert M, Crosswell HE, DesRochers TM. Abstract TMIM-069: PROSPECTIVE CLINICAL VALIDATION OF EX VIVO, PATIENT-SPECIFIC RESPONSE PREDICTION TO FIRST-LINE CHEMOTHERAPY Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-069  0.428
2019 Thiviyanathan V, Pi F, Zhang H, Li H, Wang H, Guo P, Sood A. Abstract NT-112: APTAMER CONJUGATED NANOPARTICLES FOR TARGETED DRUG DELIVERY Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Nt-112  0.408
2019 Wen Y, Wang Y, Ma S, Raicu AC, Baggerly KA, Sood AK. Abstract 3720: Blockade of the short-form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3720  0.387
2019 Rodriguez-Aguayo C, Bayraktar E, Mangala LS, Ivan C, Lopez-Berestein G, Sood AK. Abstract 3579: Long non-coding RNA ADAMTS9-AS2 inhibits ovarian tumor growth via Annexin A1 Cancer Research. 79: 3579-3579. DOI: 10.1158/1538-7445.Sabcs18-3579  0.463
2019 Kim MS, Ma S, Leuschner C, Lee S, Coleman RL, Sood AK. Abstract 3199: Targeting LHRH-R to improve immune response in ovarian cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-3199  0.376
2019 Ma S, McGuire MH, Stur E, Bayraktar E, Villar-Prados A, Wu SY, Yokoi A, Dasari SK, Rodriguez-Aguayo C, Liu J, Lopez-Berestein G, Sood AK. Abstract LB-311: Exosomal gain-of-function p53 protein promotes cancer-associated phenotype Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-311  0.461
2019 Yokoi A, Villar-Prados A, Oliphint PA, O'Halloran TJ, Roszik J, Sood AK. Abstract LB-232: A novel approach for liquid biopsy by using nExo Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-232  0.481
2019 Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, et al. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct020  0.39
2019 Lara OD, Wang Y, Hu W, Zhang L, Rauh-Hain A, Sood A. Abstract 4205: Pan-cancer molecular study of disparities among African Americans Cancer Research. 79: 4205-4205. DOI: 10.1158/1538-7445.Am2019-4205  0.46
2019 Joseph R, Soundararajan R, Vasaikar S, Yang F, Isgandarova S, Tian L, Haemmerle M, Mino B, Zhou T, Raja GV, Pena ER, Hollander PD, Bhangre N, Shin C, Martinez M, ... ... Sood A, et al. Abstract 3761: Regulation of metastasis by CD8 T lymphocytes Cancer Research. 79: 3761-3761. DOI: 10.1158/1538-7445.Am2019-3761  0.467
2019 Labrie M, Ju Z, Litton JK, Kim T, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, et al. Abstract 2070: Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers Cancer Research. 79: 2070-2070. DOI: 10.1158/1538-7445.Am2019-2070  0.384
2019 LaFargue CJ, Amero P, Noh K, Mangala S, Lu C, Cho M, Pradeep S, Wan Y, Hu W, Rupaimoole R, Coleman RL, Zhang N, An Z, Lopez-Bernstein G, Franciscis Vd, ... Sood AK, et al. Abstract 194: Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L Cancer Research. 79: 194-194. DOI: 10.1158/1538-7445.Am2019-194  0.437
2019 Kurnit KC, Sinno AK, Fellman B, Stone RL, Sood AK, Gershenson DM, Schmeler KM, Fader AN, Frumovitz M. Gastrointestinal adjuvant chemotherapy regimens improve survival outcomes in women with mucinous ovarian cancer Gynecologic Oncology. 154: 248-249. DOI: 10.1016/J.Ygyno.2019.04.573  0.381
2019 Cobb LP, Fellman B, Gershenson DM, Sood AK, Nick AM, Westin SN, Coleman RL, Fleming ND. The use of a laparoscopic surgical algorithm to triage the timing of cytoreductive surgery in patients with low grade serous ovarian and peritoneal cancer Gynecologic Oncology. 154: 247. DOI: 10.1016/J.Ygyno.2019.04.570  0.344
2019 Molin GD, Sood A, Fellman B, Coleman R, Westin S, Meyer L, Fleming N. Assessment of survival after primary treatment in ovarian cancer patients using a modified frailty index Gynecologic Oncology. 154: 209. DOI: 10.1016/J.YGYNO.2019.04.484  0.305
2019 LaFargue C, Fleming N, Nick A, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom M, Blake E, Crim A, Westin S, Coleman R, Matsuo K, Hasegawa K, Moore K, ... Sood A, et al. Diamonds in the rough: An analysis of complete pathologic responders in ovarian cancer Gynecologic Oncology. 154: 176. DOI: 10.1016/J.YGYNO.2019.04.409  0.346
2019 Lara OD, Wang Y, Zhang L, Hu W, Rauh-Hain JA, Sood AK. Think outside the box: Pan-cancer molecular study of gynecologic disparities among African Americans Gynecologic Oncology. 154: 117. DOI: 10.1016/J.Ygyno.2019.04.279  0.382
2019 LaFargue C, Villar-Prados A, Ivan C, Strovel J, Sood A. Becoming a BET inhibitor 'sommelier': Identifying the best combinations for ovarian cancer Gynecologic Oncology. 154: 68. DOI: 10.1016/J.YGYNO.2019.04.161  0.348
2019 Villar-Prados A, Ma S, LaFargue C, Roszik J, Sood AK. Predicting novel therapies and targets in ovarian and uterine cancers Gynecologic Oncology. 154: 63-64. DOI: 10.1016/J.Ygyno.2019.04.150  0.423
2019 Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, et al. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers Gynecologic Oncology. 154: 60. DOI: 10.1016/J.Ygyno.2019.04.143  0.408
2018 Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley K, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts. Cancer Letters. PMID 30503552 DOI: 10.1016/J.Canlet.2018.11.023  0.496
2018 An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. PMID 30455428 DOI: 10.1038/S41388-018-0565-9  0.511
2018 Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, ... ... Sood AK, et al. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Molecular Cancer Therapeutics. PMID 30420565 DOI: 10.1158/1535-7163.Mct-18-0365  0.364
2018 Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecologic Oncology. PMID 30366647 DOI: 10.1016/J.Ygyno.2018.10.017  0.412
2018 Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, ... ... Sood AK, et al. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics. PMID 30305341 DOI: 10.1158/1535-7163.Mct-17-1050  0.409
2018 Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, ... ... Sood AK, et al. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 34: 549-560.e9. PMID 30300578 DOI: 10.1016/J.Ccell.2018.08.019  0.4
2018 Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, et al. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecologic Oncology. PMID 30213435 DOI: 10.1016/J.Ygyno.2018.08.037  0.362
2018 Zhang L, Peng D, Sood AK, Dang CV, Zhong X. Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Molecular Cancer Therapeutics. 17: 1816-1823. PMID 30181330 DOI: 10.1158/1535-7163.Mct-18-0124  0.431
2018 Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, et al. CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Research. PMID 30115698 DOI: 10.1158/0008-5472.Can-17-3871  0.411
2018 Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Reviews. PMID 30112590 DOI: 10.1007/S10555-018-9755-8  0.366
2018 Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstetrics and Gynecology. PMID 30095787 DOI: 10.1097/Aog.0000000000002796  0.386
2018 Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Artholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30084832 DOI: 10.1158/1078-0432.Ccr-18-0504  0.346
2018 Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, ... Sood AK, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications. 9: 2923. PMID 30050129 DOI: 10.1038/S41467-018-04987-Y  0.497
2018 Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 30036226 DOI: 10.1097/Igc.0000000000001329  0.484
2018 González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martin-Salvago MD, Luque RJ, ... ... Sood AK, et al. Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30012564 DOI: 10.1158/1078-0432.Ccr-17-3125  0.39
2018 Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Therapeutic Advances in Medical Oncology. 10: 1758835918778483. PMID 29977351 DOI: 10.1177/1758835918778483  0.398
2018 Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, ... Sood AK, et al. Stress effects on FosB and interleukin-8 ()-driven ovarian cancer growth and metastasis. The Journal of Biological Chemistry. 293: 10041. PMID 29959278 DOI: 10.1074/Jbc.Aac118.004299  0.71
2018 Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK. Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Reviews. PMID 29948328 DOI: 10.1007/S10555-018-9741-1  0.303
2018 Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer. PMID 29905941 DOI: 10.1002/Cncr.31570  0.406
2018 Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, et al. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Delivery. 25: 1394-1402. PMID 29890852 DOI: 10.1080/10717544.2018.1480672  0.355
2018 Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Sood AK, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 3. PMID 29889660 DOI: 10.1172/jci.insight.122389  0.544
2018 Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 9: 25115-25126. PMID 29861857 DOI: 10.18632/Oncotarget.25344  0.488
2018 Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. Jama Oncology. PMID 29860375 DOI: 10.1001/Jamaoncol.2018.2761  0.317
2018 Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. PMID 29809169 DOI: 10.1172/Jci122301  0.471
2018 Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S. Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain, Behavior, and Immunity. PMID 29800703 DOI: 10.1016/J.Bbi.2018.05.014  0.363
2018 Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, ... ... Sood AK, et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports. 23: 823-837. PMID 29669287 DOI: 10.1016/J.Celrep.2018.03.078  0.451
2018 Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemerrle M, Gharpure KM, Rupaimoole R, Previs R, Wu SY, Pradeep S, Xu X, ... ... Sood AK, et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Research. PMID 29661830 DOI: 10.1158/0008-5472.Can-16-1701  0.681
2018 Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. PMID 29657130 DOI: 10.1016/J.Ccell.2018.03.002  0.436
2018 Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Sood AK, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014  0.404
2018 Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports. 23: 297-312.e12. PMID 29617668 DOI: 10.1016/J.Celrep.2018.03.064  0.499
2018 Vu HT, Kotla S, Ko KA, Fujii Y, Tao Y, Medina J, Thomas T, Hada M, Sood AK, Singh PK, Milgrom SA, Krishnan S, Fujiwara K, Le NT, Abe JI. Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. Frontiers in Cardiovascular Medicine. 5: 23. PMID 29594152 DOI: 10.3389/Fcvm.2018.00023  0.32
2018 Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000research. 7: 326. PMID 29560266 DOI: 10.12688/F1000Research.11771.1  0.364
2018 Liu Q, Lu C, Dai W, Li K, Xu J, Huang Y, Li G, Kang Y, Sood AK, Xu C. Association of biobehavioral factors with non-coding RNAs in cervical cancer. Bioscience Trends. 12: 24-31. PMID 29553098 DOI: 10.5582/Bst.2017.01325  0.36
2018 Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology. 8: 9. PMID 29456965 DOI: 10.3389/Fonc.2018.00009  0.37
2018 Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, ... ... Sood AK, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications. 9: 476. PMID 29396402 DOI: 10.1038/S41467-017-02811-7  0.424
2018 Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, et al. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nature Communications. 9: 461. PMID 29386624 DOI: 10.1038/S41467-018-02851-7  0.303
2018 Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley KM, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research. PMID 29386184 DOI: 10.1158/0008-5472.Can-17-1624  0.515
2018 Dood R, Zhou Y, Armbruster SD, Tworoger S, Coleman RL, Sood A, Baggerly KA. Defining survivorship and surveillance with evidence. Journal of Clinical Oncology. 36: 6528-6528. DOI: 10.1200/Jco.2018.36.15_Suppl.6528  0.351
2018 Westin SN, Litton JK, Williams RA, Shepherd CJ, Brugger W, Pease EJ, Soliman PT, Frumovitz MM, Levenback CF, Sood A, Meyer L, Moulder SL, Valero V, Saleem S, Rodriguez AM, et al. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. Journal of Clinical Oncology. 36: 5504-5504. DOI: 10.1200/Jco.2018.36.15_Suppl.5504  0.319
2018 Cho MS, Gonzalez-Pagan O, Pinto KC, Sood A, Afshar-Kharghan V. The Inhibition of Platelets Restore Anti-Tumor Immune Response to Ovarian Cancer and Its Therapeutic Implication Blood. 132: 3698-3698. DOI: 10.1182/Blood-2018-99-116530  0.445
2018 Lara OD, Rodriquez-Aguayo C, Bayrakter E, Amero P, Mangala S, LaFargue C, Tari-Ashizawa A, Lopez-Berestein G, Sood A. Abstract 5786: Grabbing GRB2: The use of liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies Cancer Research. 78: 5786-5786. DOI: 10.1158/1538-7445.Am2018-5786  0.425
2018 Ma S, Pradeep S, Wu S, Kim MS, Hu W, Mangala S, Coleman RL, Sood AK. Abstract 4817: EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor Cancer Research. 78: 4817-4817. DOI: 10.1158/1538-7445.Am2018-4817  0.482
2018 Huang T, Sood AK, Tworoger SS. Abstract 4252: Antihypertensive medication use and ovarian cancer survival Epidemiology. DOI: 10.1158/1538-7445.Am2018-4252  0.386
2018 Amero P, Rodriguez-Aguayo C, Lokesh G, Bayraktar E, Ivan C, Chaudhari R, Zhang S, Volk D, Sood A, Lopez-Berestein G. Development of novel modified aptamers to target Axl receptor in ovarian cancer Annals of Oncology. 29: iii17. DOI: 10.1093/Annonc/Mdy047.029  0.427
2018 Molin GZD, Fleming ND, Fellman B, Dood RL, Lara OD, LaFargue CJ, Coleman RL, Soliman PT, Schmeler KM, Westin SN, Sood AK. Venous thromboembolism (VTE) in ovarian cancer during neoadjuvant chemotherapy: Is it time to start prophylaxis? Gynecologic Oncology. 149: 155. DOI: 10.1016/J.Ygyno.2018.04.354  0.447
2018 LaFargue CJ, Fleming ND, Fellman B, Dood RL, Lara OD, Molin GZD, Westin SN, Coleman RL, Sood AK. From unresectable to cancer-free at interval surgery: An evaluation of complete pathologic responders Gynecologic Oncology. 149: 87. DOI: 10.1016/J.Ygyno.2018.04.199  0.371
2018 Lara OD, Rodriguez-Aguayo C, Bayraktar E, Amero P, Mangala S, LaFargue CJ, Sood AK. Grabbing the Grb2/GAB2 complex in ovarian cancer Gynecologic Oncology. 149: 60. DOI: 10.1016/J.Ygyno.2018.04.133  0.433
2018 Hansen JM, Sood AK, Coleman RL, Westin SN, Ramirez PT, Fellman B, Soliman PT, Schmeler KM, Fleming ND. Concordance of laparoscopy in predicting intraperitoneal spread and residual disease at tumor reductive surgery in advanced ovarian cancer Gynecologic Oncology. 149: 622. DOI: 10.1016/J.Ygyno.2018.03.016  0.427
2017 McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, ... ... Sood A, et al. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 29267866 DOI: 10.1093/Jnci/Djx257  0.46
2017 Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. The Journal of Clinical Investigation. PMID 29251630 DOI: 10.1172/Jci95200  0.526
2017 Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, ... ... Sood AK, et al. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. PMID 29249663 DOI: 10.1016/J.Stemcr.2017.11.010  0.442
2017 Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, ... Sood AK, et al. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy. Nucleic Acids. 9: 251-262. PMID 29246304 DOI: 10.1016/J.Omtn.2017.06.023  0.528
2017 Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Reviews. PMID 29243000 DOI: 10.1007/S10555-017-9717-6  0.325
2017 Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, et al. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. Jama Oncology. PMID 29242937 DOI: 10.1001/Jamaoncol.2017.4218  0.411
2017 Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs R, ... ... Sood AK, et al. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Molecular Cancer Therapeutics. PMID 29237804 DOI: 10.1158/1535-7163.Mct-17-0006  0.49
2017 Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, ... ... Sood AK, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 8: 96496-96505. PMID 29228548 DOI: 10.18632/Oncotarget.20410  0.356
2017 Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, ... ... Sood AK, et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports. 21: 2785-2795. PMID 29212026 DOI: 10.1016/J.Celrep.2017.11.020  0.393
2017 Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Demarzo A, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Research. PMID 29180471 DOI: 10.1158/0008-5472.Can-17-0815  0.487
2017 Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. 8: 88410-88420. PMID 29179445 DOI: 10.18632/Oncotarget.11120  0.489
2017 Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecologic Oncology. PMID 29132875 DOI: 10.1016/J.Ygyno.2017.10.026  0.461
2017 Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Sood AK, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/Jci91553  0.386
2017 Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer. PMID 29112229 DOI: 10.1002/Cncr.31078  0.414
2017 Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, ... ... Sood AK, et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. PMID 29059175 DOI: 10.1038/Onc.2017.348  0.355
2017 Hu X, Sood AK, Dang CV, Zhang L. The role of long noncoding RNAs in cancer: the dark matter matters. Current Opinion in Genetics & Development. 48: 8-15. PMID 29054012 DOI: 10.1016/J.Gde.2017.10.004  0.431
2017 Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology & Oncology. 10: 163. PMID 28985752 DOI: 10.1186/S13045-017-0525-9  0.445
2017 Chung JF, Lee SJ, Sood AK. Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget. 8: 69047-69061. PMID 28978180 DOI: 10.18632/Oncotarget.17749  0.351
2017 Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Li G, Kang Y, Xu C. Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncology Letters. 14: 2869-2877. PMID 28928826 DOI: 10.3892/Ol.2017.6521  0.343
2017 Sood AK, Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu S, Mangala LS, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28855350 DOI: 10.1158/1078-0432.Ccr-17-0647  0.637
2017 Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, ... ... Sood AK, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications. 8: 310. PMID 28827520 DOI: 10.1038/S41467-017-00411-Z  0.446
2017 Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, ... ... Sood AK, et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. Jci Insight. 2. PMID 28814667 DOI: 10.1172/Jci.Insight.93076  0.729
2017 Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecologic Oncology. PMID 28774461 DOI: 10.1016/J.Ygyno.2017.07.137  0.406
2017 Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Reviews. PMID 28730545 DOI: 10.1007/S10555-017-9682-0  0.368
2017 Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology. 84: 139-142. PMID 28711723 DOI: 10.1016/J.Psyneuen.2017.06.019  0.419
2017 Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, ... ... Sood AK, et al. PRKCI promotes immune suppression in ovarian cancer. Genes & Development. PMID 28698296 DOI: 10.1101/Gad.296640.117  0.5
2017 Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. PMID 28679740 DOI: 10.1182/Blood-2017-02-769893  0.477
2017 Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen K. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. PMID 28637314 DOI: 10.1093/Carcin/Bgx057  0.368
2017 Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Scientific Reports. 7: 3614. PMID 28620240 DOI: 10.1038/S41598-017-03972-7  0.308
2017 Hu Q, Hisamatsu T, Hammerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong ST, Sood AK, Afshar-Kharghan V. Role of platelet-derived Tgfβ1 in the progression of ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28611202 DOI: 10.1158/1078-0432.Ccr-16-3272  0.49
2017 Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, ... Sood AK, et al. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecologic Oncology. PMID 28527672 DOI: 10.1016/J.Ygyno.2017.05.008  0.348
2017 Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, ... ... Sood AK, et al. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 27380-27392. PMID 28423708 DOI: 10.18632/Oncotarget.16068  0.428
2017 Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, et al. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 8: 20145-20164. PMID 28423620 DOI: 10.18632/Oncotarget.15525  0.367
2017 Sans M, Gharpure KM, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood R, Sood AK, Eberlin L. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research. PMID 28416487 DOI: 10.1158/0008-5472.Can-16-3044  0.398
2017 Wang Y, Xu X, Yu S, Kang KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, et al. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Research. PMID 28411194 DOI: 10.1101/Gr.219741.116  0.377
2017 Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, ... ... Sood AK, et al. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 8: 17406. PMID 28403581 DOI: 10.18632/Oncotarget.15921  0.38
2017 Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, ... ... Sood AK, et al. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. Journal of the National Cancer Institute. 109. PMID 28376174 DOI: 10.1093/Jnci/Djw296  0.688
2017 Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SS. The Association of Work Characteristics With Ovarian Cancer Risk and Mortality. Psychosomatic Medicine. PMID 28306624 DOI: 10.1097/Psy.0000000000000464  0.404
2017 Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodriguez-Aguayo C, Lopez-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Molecular Cancer Therapeutics. PMID 28223424 DOI: 10.1158/1535-7163.Mct-16-0519  0.47
2017 Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecologic Oncology. PMID 28131526 DOI: 10.1016/J.Ygyno.2017.01.019  0.344
2017 Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, ... Sood AK, et al. Metastasis regulation by PPARD expression in cancer cells. Jci Insight. 2: e91419. PMID 28097239 DOI: 10.1172/Jci.Insight.91419  0.502
2017 Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, ... ... Sood A, et al. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Journal of Clinical Oncology. 35: TPS2604-TPS2604. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2604  0.456
2017 Dood R, Fleming ND, Coleman RL, Westin SN, Sood A. When advanced ovarian cancer is not ovarian cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E17066  0.457
2017 Ghazaly EA, Quesne JL, Jiang D, Mangala SL, Chettle J, Rodriguez-Aguayo C, Lopez-Berestein G, Gnanaranjan C, Mura M, Stavraka C, Sood AK, Blagden SP. Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-B30  0.478
2017 Zuo X, Xu W, Xu M, Tian R, Moussalli MJMJ, Mao F, Gagea M, Wei D, Sood AK, Shureiqi I. Abstract 844: PPARD downregulation in cancer cells suppresses metastases by inhibiting tumor angiogenesis and EMT Cancer Research. 77: 844-844. DOI: 10.1158/1538-7445.Am2017-844  0.501
2017 Lyons YA, Pradeep S, Hansen JM, Wagner MJ, Dood RL, Wu SY, Previs RA, Hu W, Coleman RL, Sood AK. Abstract 788: Less is more: macrophage depletion via CSF1/CSF1R pathway improves anti-VEGF therapy after adaptive resistance Cancer Research. 77: 788-788. DOI: 10.1158/1538-7445.Am2017-788  0.392
2017 Kheder E, Huang HJ, Wu A, Hong DS, Piha-Paul SA, Karp DD, Fu S, Subbiah V, Tsimberidou AM, Naing A, Diab A, Javle M, Kopetz S, Sood AK, Kurie JM, et al. Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers Immunology. 77: 642-642. DOI: 10.1158/1538-7445.Am2017-642  0.372
2017 McGuire MH, Herbrich S, Wu S, Wang Y, Rupaimoole R, Yao H, Gharpure K, Lopez-Berestein G, Baggerly K, Sood A. Abstract 5377: Intragenic DNA methylation and increased gene expression: New directions from pan-cancer analysis Cancer Research. 77: 5377-5377. DOI: 10.1158/1538-7445.Am2017-5377  0.354
2017 Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Noh K, Filant J, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Bartholomeusz GA, ... ... Sood AK, et al. Abstract 473: PRKRA/PACT expression promotes chemoresistance in mucinous ovarian cancer Cancer Research. 77: 473-473. DOI: 10.1158/1538-7445.Am2017-473  0.457
2017 Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Dorniak PL, ... Sood AK, et al. Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers Cancer Research. 77: 4144-4144. DOI: 10.1158/1538-7445.Am2017-4144  0.522
2017 Yang H, Zhang S, Mao W, Ahmed AA, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Le X, Lu Z, Bast RC. Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts Cancer Research. 77: 3564-3564. DOI: 10.1158/1538-7445.Am2017-3564  0.4
2017 Kanlikilicer P, Bayraktar R, Rashed M, Aslan B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 1988: Exosome-mediated ovarian cancer tumorigenesis mediated by miR1246/Rb/Cav1 axis Cancer Research. 77: 1988-1988. DOI: 10.1158/1538-7445.Am2017-1988  0.378
2017 Villar-Prados A, Wu SY, Roszik J, Sood AK, Engelhardt MI. Abstract 1528: Forecasting novel therapies by understanding the role BRD4 in regulating the Notch3 signaling in ovarian cancer Cancer Research. 77: 1528-1528. DOI: 10.1158/1538-7445.Am2017-1528  0.415
2017 Ramondetta L, Thaker P, Hu W, Urbauer D, Chisholm G, Sood A. Beta Adrenergic Blockade Is Feasible During Primary Treatment for Ovarian Cancer [10J] Obstetrics & Gynecology. 129. DOI: 10.1097/01.Aog.0000514985.46810.B0  0.379
2017 Taylor J, Westin S, Sharafi S, Jazaeri A, Frumovitz M, Soliman P, Sood A, Lu K, Savelieva K, Mills G, Vergara-Silva A, Coleman R. 992TiPN-DUR: Matched pair pharmacodynamics study of neoadjuvant durvalumab in combination with chemotherapy in frontline ovarian cancer Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx372.063  0.456
2017 Westin S, Litton J, Williams R, Soliman P, Frumovitz M, Schmeler K, Jazaeri A, Sood A, Lu K, Moulder S, Murthy R, Rodriguez A, Samuel C, Engerman L, Cyriac A, et al. 391PPhase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx367.025  0.383
2017 Fleming N, Coleman R, Westin S, Sood A. When Advanced Ovarian Cancer is not Ovarian Cancer: Characteristics and Predictors of non-Ovarian Pathology in a Systematic, Laparoscopic-Based System Gynecologic Oncology. 147: 233. DOI: 10.1016/J.Ygyno.2017.07.110  0.471
2017 Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons YA, Previs RA, Hansen JM, Dood RL, Hu W, Lichtenberger LM, Sood AK. Aspirin-PC is a novel, safe and efficacious compound in ovarian cancer Gynecologic Oncology. 145: 85-86. DOI: 10.1016/J.Ygyno.2017.03.200  0.403
2017 Hu W, Ivan C, Lyons YA, Hansen JM, Dood RL, Wagner MJ, Previs RA, Frumovitz M, Coleman RL, Sood AK. Dll3 alterations predict poor survival in gynecological cancers Gynecologic Oncology. 145: 78. DOI: 10.1016/J.Ygyno.2017.03.185  0.402
2017 Ramondetta LM, Hu W, Thaker PH, Urbauer D, Westin SN, Nagaraja AS, Ramirez PT, Fleming ND, Sahai S, Nick AM, Sood AK. No need to stress: Prospective clinical trial of adrenergic blockade during primary treatment in women with epithelial ovarian cancer Gynecologic Oncology. 145: 33-34. DOI: 10.1016/J.Ygyno.2017.03.088  0.381
2017 Thaker PH, Kuroki LM, Hu W, Zighelboim I, Ramondetta LM, Hagemann AR, Massad LS, Powell MA, Mutch DG, Sood AK. Overcoming stress effects: A prospective feasibility trial of beta-blockers with upfront ovarian cancer therapy Gynecologic Oncology. 145: 18. DOI: 10.1016/J.Ygyno.2017.03.058  0.374
2017 Dood RL, Nagaraja AS, Lyons YA, Hansen JM, Previs RA, Jackson DB, Coleman RL, Sood AK. Knocking out stress: A systems-based identification of optimal drug combinations to improve ovarian cancer outcomes Gynecologic Oncology. 145: 15. DOI: 10.1016/J.Ygyno.2017.03.053  0.356
2017 Previs R, Moss T, Zand B, Hansen J, Dood R, Armaiz-Pena G, Lyons Y, Coleman R, Sood A. Pretty fly for GPI: Altered carbohydrate metabolism in ovarian cancer Gynecologic Oncology. 145: 13. DOI: 10.1016/J.Ygyno.2017.03.047  0.67
2017 Armer JS, Schrepf A, Cuneo MG, Christensen D, Thaker PH, Slavich GM, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SK. Anxiety levels parallel changes in inflammation over time in ovarian cancer patients Brain Behavior and Immunity. 66. DOI: 10.1016/J.Bbi.2017.07.104  0.385
2016 Ravoori MK, Singh S, Bhavane R, Sood AK, Anvari B, Bankson J, Annapragada A, Kundra V. Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. Scientific Reports. 6: 38991. PMID 28004770 DOI: 10.1038/Srep38991  0.401
2016 Han HD, Byeon Y, Jang JH, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, et al. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scientific Reports. 6: 38348. PMID 27910914 DOI: 10.1038/Srep38348  0.316
2016 Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, ... ... Sood A, et al. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integrative Cancer Therapies. PMID 27903842 DOI: 10.1177/1534735416679516  0.309
2016 Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis R, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, ... ... Sood AK, et al. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903673 DOI: 10.1158/1078-0432.Ccr-16-1025  0.328
2016 Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo P. RNA Nanoparticles Harboring Annexin A2 Aptamer Can Target Ovarian Cancer for Tumor-Specific Doxorubicin Delivery. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 27890659 DOI: 10.1016/J.Nano.2016.11.015  0.377
2016 Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG. Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. Biotechniques. 61: 249-259. PMID 27839510 DOI: 10.2144/000114473  0.319
2016 Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, ... ... Sood AK, et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24: 685-700. PMID 27829138 DOI: 10.1016/J.Cmet.2016.10.011  0.495
2016 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics. PMID 27828713 DOI: 10.1080/14737159.2016.1259069  0.458
2016 Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, ... ... Sood AK, et al. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17: 1621-1631. PMID 27806300 DOI: 10.1016/J.Celrep.2016.10.020  0.474
2016 Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, ... ... Sood AK, et al. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research. 76: 6320-6330. PMID 27803105 DOI: 10.1158/0008-5472.Can-16-0854  0.485
2016 Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, ... ... Sood AK, et al. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. Jci Insight. 1: e87754. PMID 27777972 DOI: 10.1172/Jci.Insight.87754  0.422
2016 Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology & Oncology. 9: 112. PMID 27760566 DOI: 10.1186/S13045-016-0342-6  0.413
2016 Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. PMID 27742688 DOI: 10.1158/0008-5472.Can-16-0714  0.447
2016 Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, et al. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. The Journal of Pathology. PMID 27741356 DOI: 10.1002/Path.4823  0.372
2016 Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. Ebiomedicine. PMID 27720213 DOI: 10.1016/J.Ebiom.2016.09.017  0.349
2016 Grossberg A, Vichaya E, Christian D, Molkentine J, Vermeer DW, Heijnen C, Kavelaars A, Lee JH, Sood AK, Dantzer R. The Role of Neuroinflammation in Tumor-Induced Fatigue. International Journal of Radiation Oncology, Biology, Physics. 96: E562. PMID 27675023 DOI: 10.1016/J.Ijrobp.2016.06.2035  0.328
2016 Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Domiak PL, Filant J, Dial EJ, ... ... Sood AK, et al. Anti-tumor and Anti-angiogenic Effects of Aspirin-PC in Ovarian Cancer. Molecular Cancer Therapeutics. PMID 27638860 DOI: 10.1158/1535-7163.Mct-16-0074  0.501
2016 Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treatment Reviews. 50: 35-47. PMID 27612280 DOI: 10.1016/J.Ctrv.2016.08.004  0.382
2016 Huang T, Tworoger SS, Hecht JL, Rice MS, Sood AK, Kubzansky LD, Poole EM. Association of ovarian tumor β2-adrenergic receptor status with ovarian cancer risk factors and survival. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27587791 DOI: 10.1158/1055-9965.Epi-16-0534  0.479
2016 Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nature Reviews. Disease Primers. 2: 16061. PMID 27558151 DOI: 10.1038/nrdp.2016.61  0.386
2016 Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Research. 76: 3671-3675. PMID 27527638 DOI: 10.1158/0008-5472.Can-15-3100  0.43
2016 Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. PMID 27517494 DOI: 10.18632/oncotarget.11120  0.388
2016 Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, ... ... Sood AK, et al. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. PMID 27478041 DOI: 10.1016/J.Ccell.2016.06.020  0.481
2016 Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. Bba Clinical. 6: 76-81. PMID 27453821 DOI: 10.1016/J.Bbacli.2016.06.003  0.331
2016 Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh R. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. Journal of Biomedical Nanotechnology. 12: 1159-73. PMID 27319211 DOI: 10.1166/Jbn.2016.2205  0.413
2016 Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, et al. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 29: 874-888. PMID 27300436 DOI: 10.1016/J.Ccell.2016.04.016  0.387
2016 Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M, Roman LD, Sood AK. Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstetrics and Gynecology. PMID 27275802 DOI: 10.1097/Aog.0000000000001491  0.333
2016 Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan V. Platelets are not hyperreactive in patients with ovarian cancer. Platelets. 1-3. PMID 27185008 DOI: 10.3109/09537104.2016.1174204  0.421
2016 Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, et al. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. PMID 27160903 DOI: 10.1016/J.Celrep.2016.04.034  0.485
2016 Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, et al. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. PMID 27147567 DOI: 10.18632/Oncotarget.9048  0.418
2016 Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, ... Sood AK, et al. SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. PMID 27121207 DOI: 10.18632/Oncotarget.8891  0.697
2016 Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncology (London, England). PMID 27087632 DOI: 10.2217/Fon-2016-0002  0.371
2016 Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, ... ... Sood AK, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. The Journal of Clinical Investigation. PMID 27064283 DOI: 10.1172/Jci85086  0.707
2016 Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, ... ... Sood AK, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7: 11169. PMID 27041221 DOI: 10.1038/Ncomms11169  0.624
2016 Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, ... ... Sood AK, et al. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. PMID 27036018 DOI: 10.18632/Oncotarget.8412  0.404
2016 Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes & Control : Ccc. 27: 661-8. PMID 27023470 DOI: 10.1007/S10552-016-0739-0  0.481
2016 Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology. 141: 57-64. PMID 27016230 DOI: 10.1016/J.Ygyno.2016.01.004  0.42
2016 Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, ... ... Sood AK, et al. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics. PMID 27009216 DOI: 10.1158/1535-7163.Mct-15-0144  0.522
2016 Rytelewski M, Vareki SM, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. PMID 26959114 DOI: 10.18632/Oncotarget.7883  0.448
2016 Chung JF, Lee SJ, Sood AK. Immunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapies. Expert Opinion On Investigational Drugs. PMID 26954371 DOI: 10.1517/13543784.2016.1164141  0.354
2016 Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 26937753 DOI: 10.1097/Igc.0000000000000680  0.349
2016 Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. International Journal of Cancer. PMID 26934358 DOI: 10.1002/Ijc.30066  0.326
2016 Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. PMID 26918603 DOI: 10.18632/Oncotarget.7618  0.301
2016 Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery. 6: 235-46. PMID 26865249 DOI: 10.1158/2159-8290.Cd-15-0893  0.394
2016 Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. PMID 26861249 DOI: 10.1158/1535-7163.Mct-15-0733-T  0.36
2016 Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. European Journal of Cancer (Oxford, England : 1990). 56: 131-43. PMID 26849037 DOI: 10.1016/J.Ejca.2015.12.016  0.501
2016 Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, ... ... Sood AK, et al. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108. PMID 26819345 DOI: 10.1093/Jnci/Djv426  0.676
2016 Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecologic Oncology. 141: 80-5. PMID 26748214 DOI: 10.1016/J.Ygyno.2015.12.033  0.372
2016 Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, ... ... Sood AK, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. PMID 26725326 DOI: 10.1038/Onc.2015.492  0.662
2016 Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods in Molecular Biology (Clifton, N.J.). 1402: 189-97. PMID 26721492 DOI: 10.1007/978-1-4939-3378-5_15  0.401
2016 Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods in Molecular Biology (Clifton, N.J.). 1402: 33-41. PMID 26721482 DOI: 10.1007/978-1-4939-3378-5_5  0.308
2016 Westin SN, Galbraith SM, Godin R, O'Connor MJ, Munsell MF, Savelieva K, Nick AM, Soliman PT, Sood A, Mills GB, Coleman RL. WEE WIN: Window of opportunity study of induction WEE1 inhibition in advanced high-grade serous ovarian cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps5610  0.431
2016 Nick AM, Copper G, Wu W, Dantone C, Haider A, Fellman B, Davis DW, Sood A. Characterization of CTCs isolated from patients with recurrent ovarian cancer using an antibody-free CTC isolation device. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E17056  0.439
2016 Hansen JM, Ring KL, Baggerly KA, Wu S, Timms K, Neff C, Hughes E, Previs RA, Broaddus R, Coleman RL, Lu KH, Sood A. Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients. Journal of Clinical Oncology. 34: 5584-5584. DOI: 10.1200/Jco.2016.34.15_Suppl.5584  0.45
2016 Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Broaddus R, Bast R, Mills G, Sood AK, Liu J. Abstract B22: Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B22  0.456
2016 Pradeep S, Huang J, Mora E, Wu SY, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract B68: Erythropoietin stimulates ovarian tumor growth via EphB4. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B68  0.471
2016 Shoshan E, Huang L, Vasquez ME, Lee H, Kim S, Ivan C, Calin GA, Sood AK, Hwu P, Gershenwald JE, Markel G, Fidler IJ, Bar-Eli M. Abstract PR05: Control of the melanoma metastatic phenotype by A-to-I microRNA editing Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-Pr05  0.331
2016 Rashed MH, Kanlikilicer P, Aguayo CR, Kabil NN, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Mitra R, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Abstract LB-169: Ovarian cancer cells selectively release exosomes containing tumor suppressor miRNAs to maintain SRC-mediated oncogenic activities Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-169  0.42
2016 Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani A, Kuang J, Yao J, Bast R, Sood A, Hung M, Liu J. Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-119  0.45
2016 Kanlikilicer P, Rashed MMHS, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Cristian R, Bayraktar E, Picher M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Abstract 763: Exosomal miR-6126 as a novel tumor suppressor in ovarian cancer Cancer Research. 76: 763-763. DOI: 10.1158/1538-7445.Am2016-763  0.472
2016 Lyons YA, Pradeep S, Hansen JM, Previs RA, Yao H, Baggerly KA, Sood AK. Abstract 723: Distinguishing macrophages by a unique gene signature to measure response to treatment Cancer Research. 76: 723-723. DOI: 10.1158/1538-7445.Am2016-723  0.378
2016 Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi H, Stone RL, Cho MS, Nick AM, Lopez-Berestein G, Afshar-Khargan V, Sood AK. Abstract 5048: Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy Cancer Research. 76: 5048-5048. DOI: 10.1158/1538-7445.Am2016-5048  0.431
2016 Bayraktar E, Rodriguez-Aguayo C, Mai J, Ivan C, Chavez-Reyes A, Sood AK, Ferrari M, Shen H, Lopez-Berestein G. Abstract 4668: Silencing PTGER3 enhances chemotherapeutic responses Cancer Research. 76: 4668-4668. DOI: 10.1158/1538-7445.Am2016-4668  0.529
2016 Nilsson MB, Sun H, Diao L, Tong P, Fan Y, Tran H, Liu D, Pena GA, Wang J, Rowe P, Webster A, Lee J, Gomez D, Hong WK, Wistuba I, ... Sood A, et al. Abstract 4662: Beta blockers abrogate EGFR TKI resistance induced by adrenergic receptor-mediated upregulation of IL-6 and modulation of the LKB1/AMPK/mTOR axis Cancer Research. 76: 4662-4662. DOI: 10.1158/1538-7445.Am2016-4662  0.302
2016 Wen Y, Sood A. Abstract 3529: Immunotherapy targeting folate receptor induces autophagy in ovarian cancer Cancer Research. 76: 3529-3529. DOI: 10.1158/1538-7445.Am2016-3529  0.498
2016 Wagner MJ, Mitra R, Baze W, Barnhart K, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 2094: Translating EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA) to the clinic Cancer Research. 76: 2094-2094. DOI: 10.1158/1538-7445.Am2016-2094  0.305
2016 Nick AM, Coleman RL, Ramirez PT, Lu KH, Schmeler KM, Burzawa JK, Soliman PT, Rangel KM, Munsell MF, Sood AK. Personalized surgical therapy for advanced ovarian cancer: R0 resection after neoadjuvant chemotherapy is associated with decreased event-free survival compared with primary cytoreductive surgery Gynecologic Oncology. 141: 181. DOI: 10.1016/J.Ygyno.2016.04.467  0.356
2016 Nick AM, Ganeshan D, Iyer R, Bhosale P, Munsell MF, Schmeler KM, Burzawa JK, Soliman PT, Coleman RL, Sood AK. Personalizing surgical therapy for advanced ovarian cancer: CT imaging may not predict disease resectability Gynecologic Oncology. 141: 160. DOI: 10.1016/J.Ygyno.2016.04.417  0.342
2016 Sood AK, Pradeep S, Huang J, Nick AM, Brock S, Hansen J, Previs RA, Hu W, Coleman RL, Jackson DB. Off-target effects of erythropoietin stimulate ovarian cancer via EphB4 Gynecologic Oncology. 141: 45. DOI: 10.1016/J.Ygyno.2016.04.137  0.435
2016 Matsuo K, Cahoon SS, Kakuda M, Adachi S, Moeini A, Machida H, Garcia J, Ueda Y, Roman LD, Sood AK. Effect of low-dose aspirin on survival outcome of endometrial cancer Gynecologic Oncology. 141: 19. DOI: 10.1016/J.Ygyno.2016.04.075  0.366
2016 Huang Y, Hu W, Huang J, Pradeep S, Dalton H, Previs R, Hansen J, Nick A, Coleman R, Sood A. Improving hormonal therapy in uterine cancer: Efficacy of onapristone (phosphor-PR) and trametinib Gynecologic Oncology. 141: 19. DOI: 10.1016/J.Ygyno.2016.04.074  0.378
2016 Hansen JM, Previs RA, Lyons YA, Wang Y, Ivan C, Hu W, Baggerly KA, Sood AK. PTEN loss predicts response to Notch pathway inhibition in endometrial cancer Gynecologic Oncology. 141: 5-6. DOI: 10.1016/J.Ygyno.2016.04.040  0.396
2016 Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Huang J, Hansen JM, Hu W, Coleman RL, Sood AK. Two to tango: Biological activity and companion predictive markers for a novel dual AKT and P70S6K inhibitor in ovarian and uterine malignancies Gynecologic Oncology. 141: 5. DOI: 10.1016/J.Ygyno.2016.04.039  0.628
2016 Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer European Journal of Cancer. 56: 131-143. DOI: 10.1016/j.ejca.2015.12.016  0.353
2016 Lutgendorf SK, Cuneo MG, Schrepf A, Thaker PH, Goodheart M, Cole SW, Slavich GM, Sood AK. Abstract # 1740 Stress and depression levels predict neuroendocrine dynamics in long term ovarian cancer survivors Brain Behavior and Immunity. 57. DOI: 10.1016/J.Bbi.2016.07.037  0.361
2015 Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Non-Coding Rna. 1: 53-68. PMID 29861415 DOI: 10.3390/Ncrna1010053  0.405
2015 Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan V. Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. Journal of Immunology (Baltimore, Md. : 1950). PMID 26718342 DOI: 10.4049/Jimmunol.1501886  0.359
2015 Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... Sood AK, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047  0.725
2015 Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, et al. Depression and Oropharynx Cancer Outcome. Psychosomatic Medicine. PMID 26632757 DOI: 10.1097/Psy.0000000000000256  0.371
2015 Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology (Baltimore, Md.). PMID 26599259 DOI: 10.1002/Hep.28367  0.332
2015 Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram PT, Sehgal V, Lopez-Berestein G, ... ... Sood AK, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26581245 DOI: 10.1158/1078-0432.Ccr-15-1275  0.695
2015 Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK, Chiu W. Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 14266-14271. PMID 26578771 DOI: 10.1073/Pnas.1518628112  0.379
2015 Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer. Molecular Cancer Therapeutics. PMID 26516159 DOI: 10.1158/1535-7163.Mct-14-0630  0.71
2015 Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, ... ... Sood AK, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019  0.468
2015 Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, ... ... Sood AK, et al. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. PMID 26481148 DOI: 10.1016/J.Ccell.2015.09.008  0.729
2015 Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, ... ... Sood AK, et al. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 28: 529-40. PMID 26461095 DOI: 10.1016/J.Ccell.2015.09.006  0.418
2015 Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SS. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecologic Oncology. PMID 26449316 DOI: 10.1016/J.Ygyno.2015.10.004  0.357
2015 Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, ... ... Sood AK, et al. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology (Baltimore, Md.). PMID 26389641 DOI: 10.1002/Hep.28223  0.394
2015 Jiang L, Nick AM, Sood AK. Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period? Current Anesthesiology Reports. 5: 250-256. PMID 26388704 DOI: 10.1007/S40140-015-0122-9  0.493
2015 Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of MiRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. PMID 26313360 DOI: 10.18632/Oncotarget.4971  0.354
2015 Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. PMID 26301456 DOI: 10.1002/Cncr.29392  0.463
2015 Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. Nature Reviews. Cancer. 15: 563-72. PMID 26299593 DOI: 10.1038/Nrc3978  0.432
2015 Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, ... ... Sood AK, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. PMID 26257064 DOI: 10.1038/Onc.2015.302  0.75
2015 Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, ... ... Sood AK, et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer (Oxford, England : 1990). 51: 1978-88. PMID 26238017 DOI: 10.1016/J.Ejca.2015.07.012  0.308
2015 Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Molecular Cancer Therapeutics. 14: 2260-9. PMID 26227489 DOI: 10.1158/1535-7163.Mct-14-0801  0.709
2015 Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, ... ... Sood AK, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. PMID 26212011 DOI: 10.1038/Onc.2015.279  0.446
2015 Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Jama Oncology. 1: 486-94. PMID 26181259 DOI: 10.1001/Jamaoncol.2015.1432  0.406
2015 Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3121-30. PMID 26180057 DOI: 10.1158/1078-0432.Ccr-14-1189  0.387
2015 Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecologic Oncology. 138: 223-6. PMID 26166806 DOI: 10.1016/J.Ygyno.2015.07.008  0.428
2015 Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, et al. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. Plos One. 10: e0131833. PMID 26146988 DOI: 10.1371/Journal.Pone.0131833  0.486
2015 Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. Plos One. 10: e0131095. PMID 26098849 DOI: 10.1371/Journal.Pone.0131095  0.372
2015 Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer. PMID 26096769 DOI: 10.1002/Cncr.29516  0.485
2015 Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, ... ... Sood AK, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6: 7351. PMID 26081979 DOI: 10.1038/Ncomms8351  0.474
2015 Matsuo K, Hom MS, Moeini A, Machida H, Takeshima N, Roman LD, Sood AK. Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecologic Oncology. 138: 332-8. PMID 26013698 DOI: 10.1016/J.Ygyno.2015.05.019  0.455
2015 Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, ... ... Sood AK, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. Journal of the National Cancer Institute. 107. PMID 25995442 DOI: 10.1093/Jnci/Djv108  0.418
2015 Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain, Behavior, and Immunity. PMID 25989110 DOI: 10.1016/J.Bbi.2015.04.019  0.437
2015 Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MH. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle (Georgetown, Tex.). 14: 2265-73. PMID 25945542 DOI: 10.1080/15384101.2015.1046655  0.318
2015 Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520: 697-701. PMID 25901683 DOI: 10.1038/Nature14418  0.469
2015 Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, ... ... Sood AK, et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3286-97. PMID 25878333 DOI: 10.1158/1078-0432.Ccr-14-1953  0.324
2015 Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics. 14: 1466-75. PMID 25833835 DOI: 10.1158/1535-7163.Mct-14-1077  0.704
2015 Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecologic Oncology. 137: 553-8. PMID 25827290 DOI: 10.1016/J.Ygyno.2015.03.049  0.317
2015 Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, ... Sood AK, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 6: 4266-73. PMID 25738355 DOI: 10.18632/Oncotarget.2887  0.705
2015 Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nature Reviews. Clinical Oncology. 12: 239-45. PMID 25707631 DOI: 10.1038/Nrclinonc.2015.26  0.347
2015 Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, ... ... Sood AK, et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology. 17: 311-21. PMID 25686251 DOI: 10.1038/Ncb3110  0.315
2015 Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, et al. STAMP2 increases oxidative stress and is critical for prostate cancer. Embo Molecular Medicine. 7: 315-31. PMID 25680860 DOI: 10.15252/Emmm.201404181  0.377
2015 Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews. PMID 25666164 DOI: 10.1016/J.Addr.2015.01.007  0.376
2015 Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 53: 256-67. PMID 25647344 DOI: 10.1016/J.Psyneuen.2015.01.010  0.498
2015 Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, ... Sood AK, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. PMID 25639871 DOI: 10.1038/Onc.2014.469  0.376
2015 Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, ... ... Sood AK, et al. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2127-37. PMID 25595279 DOI: 10.1158/1078-0432.Ccr-14-2279  0.441
2015 Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, Zhang W. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chinese Journal of Cancer. 34: 28-40. PMID 25556616 DOI: 10.5732/Cjc.014.10284  0.466
2015 Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Reviews. 34: 19-40. PMID 25544368 DOI: 10.1007/S10555-014-9538-9  0.424
2015 Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S, Ramesh R. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Current Gene Therapy. 15: 182-92. PMID 25537774 DOI: 10.2174/1566523214666141224100612  0.337
2015 Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Current Opinion in Obstetrics & Gynecology. 27: 58-65. PMID 25502429 DOI: 10.1097/Gco.0000000000000136  0.48
2015 Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, ... Sood AK, et al. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 602-10. PMID 25473001 DOI: 10.1158/1078-0432.Ccr-14-0870  0.309
2015 Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, ... Sood AK, et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 448-59. PMID 25416196 DOI: 10.1158/1078-0432.Ccr-14-1578  0.464
2015 Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 955-61. PMID 25388163 DOI: 10.1158/1078-0432.Ccr-14-0809  0.363
2015 Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. The Journal of Pathology. 235: 25-36. PMID 25230372 DOI: 10.1002/Path.4443  0.32
2015 Feng S, Kroll MH, Nick AM, Sood A, Afshar-Kharghan V. Platelet Function in Ovarian Cancer Blood. 126: 4656-4656. DOI: 10.1182/Blood.V126.23.4656.4656  0.382
2015 Vivas-Mejia PE, Reyes j, Sood AK. Abstract B45: c-MYC is a potential therapeutic target for cisplatin-resistant ovarian cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B45  0.477
2015 Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang T, Xie X, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Abstract P6-17-01: MicroRNA-34a suppresses breast cancer bone metastasis by inhibiting osteoclastogenesis and targeting tgif2 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-17-01  0.32
2015 Wu SY, Filant J, McGuire M, Rupaimoole R, Pradeep S, Unruh A, Shelley H, Ivan C, Dennis R, Rodriguez-Aguayo C, Sehgal V, Miyake T, Nagaraja A, Gharpure K, Armaiz G, ... Sood A, et al. Abstract 5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for platinum resistance Cancer Research. 75: 5466-5466. DOI: 10.1158/1538-7445.Am2015-5466  0.503
2015 Leung CS, Yeung T, Yip K, Wong K, Sood AK, Birrer MJ, Mok SC. Abstract 4184: CAF-derived MFAP5 promotes tumor angiogenesis and confers paclitaxel resistance in high-grade serous ovarian cancer Cancer Research. 75: 4184-4184. DOI: 10.1158/1538-7445.Am2015-4184  0.55
2015 Granados-Principal S, Liu Y, Rodriguez-Aguayo C, Sood AK, Chang JC. Abstract 4086: HMG Box Domain Containing 3 (HMGXB3), a novel TGFβ-induced cancer gene that influences cancer stem cells and metastasis in triple negative breast cancer Cancer Research. 75: 4086-4086. DOI: 10.1158/1538-7445.Am2015-4086  0.434
2015 Napoli M, Venkatanarayan A, Raulji P, Abbas HA, Norton W, Sood AK, Lopez-Berestein G, Tsai KY, Coarfa C, Gunaratne PH, Flores ER. Abstract 3975: Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutant tumors Cancer Research. 75: 3975-3975. DOI: 10.1158/1538-7445.Am2015-3975  0.402
2015 Wen Y, Sood AK. Abstract 3817: Suicidal autophagy induced by immunotherapy targeting folate receptor in ovarian cancer Cancer Research. 75: 3817-3817. DOI: 10.1158/1538-7445.Am2015-3817  0.529
2015 Nagaraja AS, Dorniak P, Sadaoui N, Armaiz-Pena G, Zand B, Wu SY, Allen JK, Rupaimoole R, Rodriguez-Aguayo C, Pradeep S, Tan L, Previs RA, Hansen JM, Yang P, Lopez-Berestein G, ... ... Sood AK, et al. Abstract 3368: Sustained adrenergic signaling activates pro-inflammatory prostaglandin network in ovarian carcinoma Cancer Research. 75: 3368-3368. DOI: 10.1158/1538-7445.Am2015-3368  0.705
2015 Raghavan PC, Pradeep S, Lu Y, Sood A, Mills G. Abstract 3072: miR-551b amplification regulates STAT3 expression and resistance to anoikis of ovarian cancer cells Cancer Research. 75: 3072-3072. DOI: 10.1158/1538-7445.Am2015-3072  0.466
2015 Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Dorniak P, Previs R, Sadaoui N, Stone R, Matsuo K, Dalton HJ, Lutgendorf SK, Sood AK, Lopez-Berestein G. Abstract 2359: Adrenergic regulation of MCP-1 leads to enhanced macrophage recruitment and ovarian carcinoma growth Cancer Research. 75: 2359-2359. DOI: 10.1158/1538-7445.Am2015-2359  0.718
2015 Liu Y, Choi DS, Grandos-Principal S, Qian W, Burey L, Wong H, Rodriguez-Aguayo C, Sood A, Li Z, Wong S, Weiss H, Dave B, Landis M, Chang JC. Abstract 2312: Identifying novel cancer stem cell target for triple-negative breast cancer Cancer Research. 75: 2312-2312. DOI: 10.1158/1538-7445.Am2015-2312  0.5
2015 Gharpure KM, Tucker SL, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, ... ... Sood A, et al. Abstract 2273: Mechanistic and functional implications of FABP4 in ovarian cancer metastasis Cancer Research. 75: 2273-2273. DOI: 10.1158/1538-7445.Am2015-2273  0.482
2015 Hansen JM, Baggerly K, Wang Y, Ivan C, Wu S, Previs R, Zand B, Dalton H, Hu W, Coleman RL, Sood AK. Abstract 2165: Concurrent BRCA2 and PTEN mutations are associated with improved survival in endometrioid endometrial cancer Cancer Research. 75: 2165-2165. DOI: 10.1158/1538-7445.Am2015-2165  0.359
2015 Pradeep S, Huang J, Mora E, Nick A, Cho M, Wu S, Rupaimoole R, Xiong C, Li C, Lopez-Berestein G, Jackson D, Sood A. Abstract 1952: Adverse effects of erythropoietin stimulates tumor growth via EphB4 Cancer Research. 75: 1952-1952. DOI: 10.1158/1538-7445.Am2015-1952  0.455
2015 Rupaimole R, Previs R, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison J, Rodriguez-Aguayo C, Calin GA, Mills G, Zhang W, Lopez-Berestein G, Bhattacharya P, Sood AK. Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells Cancer Research. 75: 142-142. DOI: 10.1158/1538-7445.Am2015-142  0.406
2015 Yang L, Achreja A, Moss T, Baddour J, Stilles K, Chiba L, Kim SH, Morse J, Marini J, Sood AK, Ram PT, Nagrath D. Abstract 1208: Glutamine modulates cellular NAD+/NADH homeostasis thereby regulating cancer metastasis, drug sensitivity in cancer cells Cancer Research. 75: 1208-1208. DOI: 10.1158/1538-7445.Am2015-1208  0.512
2015 Previs RA, Moss TJ, Zand B, Rupaimoole R, Dalton HJ, Hansen JM, Armaiz-Pena G, Lutgendorf S, Coleman RL, Bhattacharya P, Ram P, Sood AK. Abstract 1199: Systems-based approach identifies altered carbohydrate metabolism as a predictor of a malignant phenotype in ovarian cancer Cancer Research. 75: 1199-1199. DOI: 10.1158/1538-7445.Am2015-1199  0.659
2015 Choi DS, Yi L, Rodriguez-Aguayo C, Dave B, Wong STC, Sood AK, Chang JC. Abstract LB-C09: Hematological and Neurological Expressed 1-Like (HN1L) is a Novel Therapeutic Target for Triple Negative Breast Cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C09  0.459
2015 Fleming ND, Coleman RL, Tung CS, Munsell MF, Sood AK. Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer Gynecologic Oncology. 137: 79. DOI: 10.1016/J.Ygyno.2015.01.194  0.362
2015 Zand B, Previs R, Zacharias N, Rupaimoole R, Dalton H, Hansen J, Rodriguez-Aguayo C, Guindani M, Lopez-Berestein G, Bhattacharya P, Sood A. Role of increased n-acetylaspartate levels in epithelial ovarian cancer Gynecologic Oncology. 137: 68. DOI: 10.1016/J.Ygyno.2015.01.161  0.422
2015 Previs R, Moss T, Zand B, Rupaimoole R, Dalton H, Hansen J, Armaiz-Pena G, Lutgendorf S, Coleman R, Bhattacharya P, Ram P, Sood A. Fuel for the fire: Connecting genomics with metabolomics in ovarian cancer Gynecologic Oncology. 137: 67. DOI: 10.1016/J.Ygyno.2015.01.157  0.649
2015 Sood AK, Huang J, Hu W, Previs RA, Dalton HJ, Hansen JM, Sun Y, Nick AM, Broaddus R, Coleman RL. Molecular predictors of response to EphA2 targeted therapy in uterine cancer Gynecologic Oncology. 137: 59. DOI: 10.1016/J.Ygyno.2015.01.137  0.398
2015 Previs RA, Thanapprapasr D, Hu W, Rupaimoole R, Huang J, Dalton HJ, Ali R, Armaiz-Pena GN, Hansen JM, Zand B, Coleman RL, Sood AK. The FAK of uterine cancer: PTEN expression predicts response of uterine cancer to focal adhesion kinase inhibition Gynecologic Oncology. 137: 59. DOI: 10.1016/J.Ygyno.2015.01.136  0.685
2015 Hansen JM, Baggerly KA, Wang Y, Wu S, Previs RA, Zand B, Dalton HJ, Hu W, Coleman RL, Sood AK. Homologous recombination deficiency in endometrioid uterine cancer: An unrecognized phenomenon Gynecologic Oncology. 137: 21. DOI: 10.1016/J.Ygyno.2015.01.048  0.434
2015 Nick AM, Coleman RL, Ramirez PT, Schmeler KM, Soliman PT, Lu KH, Burzawa JK, Sood AK. Personalized surgical therapy for advanced ovarian cancer Gynecologic Oncology. 137: 10. DOI: 10.1016/J.Ygyno.2015.01.022  0.411
2015 Lutgendorf S, Thaker P, Slavich G, Goodheart M, Bender D, Dahmoush L, Lubaroff D, Penedo F, DeGeest K, Arevalo J, Sood A, Cole S. Beta-adrenergic activation of Epithelial-Mesenchymal Transition in ovarian cancer Brain, Behavior, and Immunity. 49: e1-e2. DOI: 10.1016/J.Bbi.2015.06.028  0.504
2015 Taylor M, Coleman RL, Sood AK. The Role of Angiogenesis in Cancer Translational Cancer Research. 64-71. DOI: 10.1002/9781118468678.Ch6  0.466
2014 Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, ... ... Sood AK, et al. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 26: 863-79. PMID 25490449 DOI: 10.1016/J.Ccell.2014.10.010  0.328
2014 Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, et al. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. Journal of Ovarian Research. 7: 109. PMID 25477184 DOI: 10.1186/S13048-014-0109-Z  0.302
2014 Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications. 5: 5671. PMID 25476932 DOI: 10.1038/Ncomms6671  0.336
2014 van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MH, Yao CQ, Ivan M, Ivan C, Pecot CV, ... ... Sood AK, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications. 5: 5203. PMID 25351418 DOI: 10.1038/Ncomms6203  0.401
2014 Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, ... ... Sood AK, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications. 5: 5202. PMID 25351346 DOI: 10.1038/Ncomms6202  0.612
2014 Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L. Mind-body practices in cancer care. Current Oncology Reports. 16: 417. PMID 25325936 DOI: 10.1007/S11912-014-0417-X  0.356
2014 Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, ... ... Sood AK, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Molecular Cancer Therapeutics. 13: 2876-85. PMID 25281617 DOI: 10.1158/1535-7163.Mct-14-0074  0.472
2014 Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications. 5: 5092. PMID 25277212 DOI: 10.1038/Ncomms6092  0.726
2014 Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. Journal of the National Cancer Institute. 106. PMID 25214561 DOI: 10.1093/Jnci/Dju245  0.318
2014 Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, ... ... Sood AK, et al. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics. 13: 2583-94. PMID 25193509 DOI: 10.1158/1535-7163.Mct-14-0028  0.663
2014 Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Reports. 8: 1447-60. PMID 25176654 DOI: 10.1016/J.Celrep.2014.07.058  0.328
2014 Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prevention Research (Philadelphia, Pa.). 7: 973-92. PMID 25060262 DOI: 10.1158/1940-6207.Capr-14-0079  0.451
2014 Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, ... Sood AK, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 26: 77-91. PMID 25026212 DOI: 10.1016/J.Ccr.2014.05.002  0.517
2014 Davis AN, Afshar-Kharghan V, Sood AK. Platelet effects on ovarian cancer. Seminars in Oncology. 41: 378-84. PMID 25023353 DOI: 10.1053/J.Seminoncol.2014.04.004  0.416
2014 Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Molecular Oncology. 8: 1429-40. PMID 24974076 DOI: 10.1016/J.Molonc.2014.05.017  0.506
2014 Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, ... ... Sood A, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.Can-14-0584  0.397
2014 Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, ... Sood AK, et al. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecologic Oncology. 134: 6-9. PMID 24952408 DOI: 10.1016/J.Ygyno.2014.04.042  0.409
2014 Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Science Translational Medicine. 6: 240ps7. PMID 24920658 DOI: 10.1126/Scitranslmed.3008362  0.357
2014 Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology & Therapy. 15: 1061-7. PMID 24841852 DOI: 10.4161/Cbt.29184  0.489
2014 Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, ... Sood AK, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 10: 728. PMID 24799285 DOI: 10.1002/Msb.20134892  0.732
2014 Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ikeda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, ... Sood AK, et al. Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstetrics and Gynecology. 123: 957-65. PMID 24785846 DOI: 10.1097/Aog.0000000000000240  0.419
2014 Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Research. 74: 3556-66. PMID 24769442 DOI: 10.1158/0008-5472.Can-13-3225  0.353
2014 Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, ... ... Sood AK, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3280-8. PMID 24756370 DOI: 10.1158/1078-0432.Ccr-14-0445  0.376
2014 Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, ... ... Sood AK, et al. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biology & Therapy. 15: 919-29. PMID 24755674 DOI: 10.4161/Cbt.28882  0.704
2014 Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, ... Sood AK, et al. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Molecular Cancer Therapeutics. 13: 1750-7. PMID 24755199 DOI: 10.1158/1535-7163.Mct-13-0930  0.694
2014 Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, ... ... Sood AK, et al. Notch3 pathway alterations in ovarian cancer. Cancer Research. 74: 3282-93. PMID 24743243 DOI: 10.1158/0008-5472.Can-13-2066  0.478
2014 Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. European Journal of Cancer (Oxford, England : 1990). 50: 1638-48. PMID 24709487 DOI: 10.1016/J.Ejca.2014.03.005  0.368
2014 Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America. 111: 5331-6. PMID 24706848 DOI: 10.1073/Pnas.1317242111  0.39
2014 Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, ... ... Sood AK, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Reports. 7: 488-500. PMID 24703838 DOI: 10.1016/J.Celrep.2014.03.009  0.475
2014 Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Reviews. 33: 231-69. PMID 24696047 DOI: 10.1007/S10555-014-9498-0  0.367
2014 Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecologic Oncology. 133: 473-9. PMID 24674832 DOI: 10.1016/J.Ygyno.2014.03.563  0.414
2014 Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, ... Sood AK, et al. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2740-50. PMID 24634380 DOI: 10.1158/1078-0432.Ccr-13-2507  0.495
2014 Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Sood AK, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/Ncomms4459  0.653
2014 Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, ... ... Sood AK, et al. Autocrine effects of tumor-derived complement. Cell Reports. 6: 1085-95. PMID 24613353 DOI: 10.1016/J.Celrep.2014.02.014  0.5
2014 Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, Xue F, Zhang W. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. The Journal of Pathology. 233: 308-18. PMID 24604117 DOI: 10.1002/Path.4348  0.375
2014 Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. Journal of Hematology & Oncology. 7: 19. PMID 24598126 DOI: 10.1186/1756-8722-7-19  0.338
2014 Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Research. 74: 1287-93. PMID 24556724 DOI: 10.1158/0008-5472.Can-13-2825  0.684
2014 Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A, Lee JS. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research. 34: 811-7. PMID 24511017  0.389
2014 Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, ... ... Sood AK, et al. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1846-55. PMID 24486585 DOI: 10.1158/1078-0432.Ccr-13-2141  0.364
2014 Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative beta-blocker use and survival in lung cancer patients. Journal of Clinical Anesthesia. 26: 106-17. PMID 24480297 DOI: 10.1016/J.Jclinane.2013.10.004  0.342
2014 Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. Journal of Liposome Research. 24: 182-90. PMID 24443972 DOI: 10.3109/08982104.2013.863208  0.312
2014 Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Advanced Drug Delivery Reviews. 66: 110-6. PMID 24384374 DOI: 10.1016/J.Addr.2013.12.008  0.426
2014 Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 35: 1100-9. PMID 24379240 DOI: 10.1093/Carcin/Bgt489  0.446
2014 Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecologic Oncology. 132: 166-75. PMID 24183729 DOI: 10.1016/J.Ygyno.2013.10.027  0.325
2014 Cho MS, Hu Q, Rupaimoole R, Sood A, Afshar-Kharghan V. Complement Component 3 (C3) Is a Mediator of Epithelial-Mesenchymal Transition (EMT) Blood. 124: 1421-1421. DOI: 10.1182/Blood.V124.21.1421.1421  0.37
2014 Pecot C, Wu S, Bellister S, Bhattacharya R, Maharaj A, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Lopez-Berestein G, Ellis LM, Sood A. Abstract B47: Therapeutic KRAS silencing in lung and colon cancer models Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B47  0.452
2014 Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han H, Rupaimoole R, Wu SY, Dalton HJ, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Abstract 5403: Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer Cancer Research. 74: 5403-5403. DOI: 10.1158/1538-7445.Am2014-5403  0.392
2014 Shoshan E, Mobley A, Braeuer R, Kamiya T, Huang L, Vasquez M, Jeong LH, kim SJ, Calin G, Sood A, Markel G, Fidler I, Bar-Eli M. Abstract 4969: Hypo adenosine-to-inosine editing of microRNA-455 promotes melanoma metastasis Cancer Research. 74: 4969-4969. DOI: 10.1158/1538-7445.Am2014-4969  0.344
2014 Pradeep S, Kim SW, Wu S, Masato N, Miyake T, Hyun-Jin C, Rupaimoole R, Liu J, Fidler I, Lopez G, Sood A. Abstract 4954: Hematogenous metastasis of ovarian cancer: Re-thinking mode of spread Cancer Research. 74: 4954-4954. DOI: 10.1158/1538-7445.Am2014-4954  0.529
2014 Jiang D, Mangala LS, Wang H, Wu S, Rao LG, Rodriguez-Aguayo C, Pradeep S, Volk DE, Lopez-Berestein G, Sood AK. Abstract 4468: Tumor vasculature targeting using cell-specific thioaptamer decorated chitosan nanoparticle Cancer Research. 74: 4468-4468. DOI: 10.1158/1538-7445.Am2014-4468  0.429
2014 Chaluvally-Raghavan P, Zhang F, Liu W, Tyler M, Yu S, Pradeep S, Ram P, Lu Y, Sood A, Mills G. Abstract 4396: MicroRNA MIR551B amplified at 3q26.2 locus activate c-KIT expression and causes resistance to anoikis of ovarian cancer cells Cancer Research. 74: 4396-4396. DOI: 10.1158/1538-7445.Am2014-4396  0.492
2014 Reyes-González JM, Armaiz GN, Mangala LS, Valiyeva F, Pradeep S, Sood AK, Vivas-Mejía PE. Abstract 3761: Nanoliposomal c-MYC-siRNA inhibitsin vivotumor growth of cisplatin-resistant ovarian cancer Cancer Research. 74: 3761-3761. DOI: 10.1158/1538-7445.Am2014-3761  0.51
2014 Rupaimoole R, Ivan C, Pecot C, Wu S, Pradeep S, Zand B, Nagaraja A, Gharpure K, Dalton H, Sadaoui N, Zhang W, Lopez-Berestein G, Sood A. Abstract 3532: Hypoxia is a master regulator of Drosha- and Dicer-dependent miRNA biogenesis in cancer Cancer Research. 74: 3532-3532. DOI: 10.1158/1538-7445.Am2014-3532  0.38
2014 Sadaoui NC, Armaiz-Pena GN, Nagaraja AS, Rupaimoole R, Previs RA, Dalton HJ, Lingegowda MS, Ramondetta LM, Sood AK, Lutgendorf SK, Cole SW. Abstract 3511: Sustained adrenergic signaling promotes cervical cancer progression Cancer Research. 74: 3511-3511. DOI: 10.1158/1538-7445.Am2014-3511  0.705
2014 Yang L, Moss TJ, Marini JC, Mangala S, Wahlig S, Win J, Su D, Sood AK, Ram PT, Nagrath D. Abstract 3377: Glutamine mediated aggressiveness and drug sensitivity in ovarian cancer cells Cancer Research. 74: 3377-3377. DOI: 10.1158/1538-7445.Am2014-3377  0.461
2014 Previs RA, Ivan C, Dalton HJ, Davis AN, Bottsford-Miller JN, Zand B, McGuire MH, Armaiz-Pena GN, Coleman RL, Baggerly KA, Sood AK. Abstract 3340: Exploiting the non-overlapping dysregulation of Notch and PI3K/AKT signaling pathways as a guide for personalizing uterine cancer therapy Cancer Research. 74: 3340-3340. DOI: 10.1158/1538-7445.Am2014-3340  0.699
2014 Davis AN, Lin-Liu YG, Previs RA, Dalton HJ, Zand B, Bottsford-Miller J, Coleman R, Sood AK. Abstract 2995: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer Cancer Research. 74: 2995-2995. DOI: 10.1158/1538-7445.Am2014-2995  0.492
2014 Huang J, Hu W, Dalton HJ, Bottsford-Miller J, Coleman RL, Jaffe RB, Sood AK. Abstract 2993: Dll4 inhibition plus aflibercept markedly reduces ovarian tumor burden and ascites Cancer Research. 74: 2993-2993. DOI: 10.1158/1538-7445.Am2014-2993  0.472
2014 Gonzalez-Villasana V, Rodriguez-Aguayo C, Fuentes-Mattei E, Pradeep S, Ivan C, Sood AK, Lopez-Berestein G. Abstract 2992: Zoledronic acid inhibits angiogenesis through Rac1 inactivation in ovarian cancer Cancer Research. 74: 2992-2992. DOI: 10.1158/1538-7445.Am2014-2992  0.475
2014 Dalton HJ, Reusser NM, Zien A, Jackson D, Previs R, Rupaimoole R, Zand B, Lopez-Berestein G, Coleman RL, Sood AK. Abstract 2983: Bisphosphonates: New strategies for targeting angiogenesis in ovarian cancer Cancer Research. 74: 2983-2983. DOI: 10.1158/1538-7445.Am2014-2983  0.519
2014 Dalton HJ, Pradeep S, Armaiz-Pena GN, Previs R, Davis A, Rupaimoole R, Zand B, Hailemichael Y, Overwijk WW, Lopez-Berestein G, Sood AK. Abstract 2982: Macrophages modulate adaptive resistance to anti-angiogenic therapy Cancer Research. 74: 2982-2982. DOI: 10.1158/1538-7445.Am2014-2982  0.668
2014 Nagaraja AS, Armaiz-Pena G, Allen J, Sadaoui NC, Zand B, Yang P, Tan L, Cole S, Lutgendorf S, Sood AK. Abstract 158: Sustained adrenergic signaling activates pro-inflammatory networks in ovarian carcinoma Cancer Research. 74: 158-158. DOI: 10.1158/1538-7445.Am2014-158  0.704
2014 Shah M, Lopez GB, Sood A, Calin G. Abstract 1455: Therapeutic synergy between novel tumor suppressor miR-520d-3p and EphA2-targeting siRNA in ovarian cancer Cancer Research. 74: 1455-1455. DOI: 10.1158/1538-7445.Am2014-1455  0.45
2014 Wen Y, Graybill WS, Sood A. Abstract 1330: Immunotherapy targeting folate receptor induces autophagy in ovarian cancer Cancer Research. 74: 1330-1330. DOI: 10.1158/1538-7445.Am2014-1330  0.494
2014 Armaiz-Pena GN, Nagaraja AS, Allen JK, Sadaoui NC, Rupaimoole R, wu sY, Pradeep S, Han HD, Zand B, Dalton H, Previs R, Taylor M, Bottsford-Miller J, Mangala LS, Rodriguez-Aguayo C, ... ... Sood AK, et al. Abstract 1062: Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction Cancer Research. 74: 1062-1062. DOI: 10.1158/1538-7445.Am2014-1062  0.706
2014 Leung CS, Yeung T, Yip K, Wong K, Sood AK, Birrer MJ, Mok SC. Abstract 1029: CAF-derived MFAP5 promotes ovarian tumor angiogenesis through calcium dependent LPP signaling pathway Cancer Research. 74: 1029-1029. DOI: 10.1158/1538-7445.Am2014-1029  0.494
2014 King ER, Coleman RL, Urbauer D, Fellman B, Sood AK, Nick AM. Out with the old and in with the neoadjuvant: Changes and influences in ovarian cancer practice patterns among Society of Gynecologic Oncology (SGO) members Gynecologic Oncology. 133: 143. DOI: 10.1016/J.Ygyno.2014.03.374  0.393
2014 Previs RA, Ivan C, Dalton HJ, Davis AN, Bottsford-Miller JN, Zand B, Coleman RL, Baggerly KA, Sood AK. Taking it up a Notch: Implications for outcomes in endometrial cancer Gynecologic Oncology. 133: 132-133. DOI: 10.1016/J.Ygyno.2014.03.346  0.395
2014 Hu W, Liu T, Ivan C, Huang J, Dalton H, Previs R, Nick A, Lopez-Berestein G, Coleman R, Sood A. Selective activation of Notch3 in high-grade serous ovarian cancer Gynecologic Oncology. 133: 115. DOI: 10.1016/J.Ygyno.2014.03.304  0.439
2014 Davis AN, Ivan C, Previs RA, Dalton HJ, Bottsford-Miller JN, Zand B, Coleman RL, Baggerly KA, Sood AK. Hitting the right mark: Nonoverlapping Notch and PI3K alterations in ovarian cancer Gynecologic Oncology. 133: 96. DOI: 10.1016/J.Ygyno.2014.03.256  0.456
2014 Matsuo K, Yoshino K, Nishimura M, Hiramatsu K, Banzai C, Sheridan TB, Hasegawa K, Shiki Y, Roman LD, Sood AK. Impact of lymphovascular space invasion (LVSI) on survival of stage I epithelial ovarian cancer Gynecologic Oncology. 133: 85. DOI: 10.1016/J.Ygyno.2014.03.227  0.398
2014 Davis AN, Lin YG, Previs RA, Dalton HJ, Stone RL, Bottsford-Miller JN, Zand B, Coleman RL, Sood AK, Taylor M. A dose a day keeps the cancer away: Metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer Gynecologic Oncology. 133: 71. DOI: 10.1016/J.Ygyno.2014.03.191  0.445
2014 Dalton HJ, Reusser NM, Zien A, Previs RA, Rupaimoole R, Zand B, Bottsford-Miller JN, Nick AM, Coleman RL, Sood AK. Not your mother's bisphosphonate: Targeting angiogenesis in ovarian cancer Gynecologic Oncology. 133: 42. DOI: 10.1016/J.Ygyno.2014.03.122  0.443
2014 Nick AM, Ramirez PT, Rangel KM, Schmeler KM, Soliman PT, Burzawa JK, Kodama M, Lu KH, Coleman RL, Sood AK. Launching personalized surgical therapy for advanced ovarian cancer Gynecologic Oncology. 133: 28. DOI: 10.1016/J.Ygyno.2014.03.089  0.411
2014 Tucker S, Gharpure K, Herbrich S, Nick A, King E, Coleman R, Guenthoer J, Dalton H, Baggerly K, Sood A. Molecular predictors of residual disease in patients with ovarian cancer Gynecologic Oncology. 133: 25. DOI: 10.1016/J.Ygyno.2014.03.081  0.354
2014 Bottsford-Miller JN, Taylor M, Dalton HJ, Stone RL, Nick AM, Davis AN, Zand B, Previs RA, Afshar-Kharghan V, Sood AK. More is not always better: Thrombocytosis contributes to impaired chemotherapy response in ovarian cancer Gynecologic Oncology. 133: 20-21. DOI: 10.1016/J.Ygyno.2014.03.071  0.438
2014 Bottsford-Miller JN, Taylor M, Dalton HJ, Stone RL, Nick AM, Davis AN, Zand B, Previs RA, Afshar-Kharghan V, Sood AK. Wound healing gone awry: Role for platelets in tumor growth after antiangiogenic therapy Gynecologic Oncology. 133: 19. DOI: 10.1016/J.Ygyno.2014.03.068  0.305
2013 Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, ... ... Sood AK, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 155: 552-66. PMID 24243015 DOI: 10.1016/J.Cell.2013.09.041  0.383
2013 Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. Plos One. 8: e79167. PMID 24236104 DOI: 10.1371/Journal.Pone.0079167  0.496
2013 Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, ... ... Sood AK, et al. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6532-43. PMID 24100628 DOI: 10.1158/1078-0432.Ccr-13-1305  0.328
2013 Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, Mendez L, Collins K, Sood AK. Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecologic Oncology. 131: 667-73. PMID 24096110 DOI: 10.1016/J.Ygyno.2013.09.025  0.383
2013 Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. Journal of Drug Targeting. 21: 904-13. PMID 24079419 DOI: 10.3109/1061186X.2013.837469  0.399
2013 Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, ... ... Sood AK, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. Journal of the National Cancer Institute. 105: 1485-95. PMID 24062525 DOI: 10.1093/Jnci/Djt210  0.432
2013 Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 2102-9. PMID 24045927 DOI: 10.1158/1055-9965.Epi-13-0625  0.462
2013 Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Molecular Therapy. Nucleic Acids. 2: e121. PMID 24022053 DOI: 10.1038/Mtna.2013.45  0.426
2013 Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, ... ... Sood AK, et al. Tumour angiogenesis regulation by the miR-200 family. Nature Communications. 4: 2427. PMID 24018975 DOI: 10.1038/Ncomms3427  0.355
2013 Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, ... ... Sood AK, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery. 3: 1302-15. PMID 24002999 DOI: 10.1158/2159-8290.Cd-13-0159  0.404
2013 Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK. β-blockers: a new role in cancer chemotherapy? Expert Opinion On Investigational Drugs. 22: 1359-1363. PMID 23919278 DOI: 10.1517/13543784.2013.825250  0.375
2013 Thaker PH, Sood AK, Ramondetta LM. Importance of adrenergic pathways in women's cancers Criminal Behaviour and Mental Health. 13: 145-154. PMID 23912486 DOI: 10.3233/Cbm-130324  0.368
2013 Melhem-Bertrandt A, Sood AK. Adrenergic signaling and cancer: Deciphering the connections Cancer Biomarkers. 13: 131-132. PMID 23912484 DOI: 10.3233/Cbm-130333  0.386
2013 Gharpure KM, Sood AK. Neighborhood matters: Response to EZH2 methyltransferase inhibitors Cell Cycle. 12: 2345. PMID 23887388 DOI: 10.4161/Cc.25775  0.44
2013 Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, ... ... Sood AK, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 24: 229-41. PMID 23871637 DOI: 10.1016/J.Ccr.2013.06.004  0.439
2013 Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecologic Oncology. 130: 565-9. PMID 23800698 DOI: 10.1016/J.Ygyno.2013.06.016  0.373
2013 Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E2572-81. PMID 23798432 DOI: 10.1073/Pnas.1304318110  0.363
2013 Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 815-22. PMID 23669443 DOI: 10.1097/Igc.0B013E31828F7A24  0.38
2013 Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, ... ... Sood AK, et al. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia (New York, N.Y.). 15: 502-10. PMID 23633922 DOI: 10.1593/Neo.121412  0.394
2013 Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation. 123: 2119-30. PMID 23585472 DOI: 10.1172/JCI65425  0.367
2013 Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia (New York, N.Y.). 15: 409-20. PMID 23555186 DOI: 10.1593/Neo.121228  0.449
2013 Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology. 3: 58. PMID 23519775 DOI: 10.3389/Fonc.2013.00058  0.452
2013 Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, ... ... Sood AK, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23: 186-99. PMID 23410973 DOI: 10.1016/J.Ccr.2012.12.020  0.337
2013 Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology (Baltimore, Md.). 58: 182-91. PMID 23389994 DOI: 10.1002/Hep.26310  0.385
2013 Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, ... ... Sood AK, et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1806-15. PMID 23386691 DOI: 10.1158/1078-0432.Ccr-12-2764  0.441
2013 Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer Nature Reviews Clinical Oncology. 10: 211-224. PMID 23381004 DOI: 10.1038/Nrclinonc.2013.5  0.418
2013 Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, ... ... Sood AK, et al. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nature Communications. 4: 1403. PMID 23360994 DOI: 10.1038/Ncomms2413  0.691
2013 Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. The Journal of Clinical Investigation. 123: 558-60. PMID 23348736 DOI: 10.1172/Jci67887  0.697
2013 Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 809-20. PMID 23344261 DOI: 10.1158/1078-0432.Ccr-12-2736  0.487
2013 Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecologic Oncology. 129: 86-91. PMID 23321064 DOI: 10.1016/J.Ygyno.2013.01.006  0.357
2013 Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecologic Oncology. 128: 506-11. PMID 23200915 DOI: 10.1016/J.Ygyno.2012.11.029  0.446
2013 Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer Expert Opinion On Biological Therapy. 13: 283-294. PMID 23190436 DOI: 10.1517/14712598.2012.745508  0.407
2013 Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 170-82. PMID 23147994 DOI: 10.1158/1078-0432.Ccr-12-1045  0.493
2013 Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, ... ... Sood AK, et al. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain, Behavior, and Immunity. 30: S126-34. PMID 22884960 DOI: 10.1016/J.Bbi.2012.07.022  0.367
2013 Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi R. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecologic Oncology. 128: 344-8. PMID 22871469 DOI: 10.1016/J.Ygyno.2012.07.128  0.402
2013 Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Letters. 330: 123-9. PMID 22776561 DOI: 10.1016/J.Canlet.2012.07.001  0.481
2013 Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. Brain, Behavior, and Immunity. 30: S19-25. PMID 22728325 DOI: 10.1016/J.Bbi.2012.06.005  0.734
2013 Cho MS, Rupaimoole R, Sood A, Afshar-Kharghan V. Complement Component 3 (C3) Is Transcriptionally Regulated By TWIST1 Blood. 122: 1046-1046. DOI: 10.1182/Blood.V122.21.1046.1046  0.371
2013 Moreno-Smith M, Halder J, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, ... ... Sood AK, et al. ATP11B mediates platinum resistance in ovarian cancer Journal of Clinical Investigation. 123: 5411-5411. DOI: 10.1172/Jci73904  0.435
2013 Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, Brabander JD, Komurov K, Posner BA, ... ... Sood AK, et al. Abstract C16: Mapping synthetic vulnerabilities in non-small cell lung cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-C16  0.468
2013 Pecot CV, Maharaj A, Wu S, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Zand B, Arumugam T, Lopez G, Sood A. Abstract 938: Silencing the elephant in the room: therapeutic KRAS targeting with siRNA. Cancer Research. 73: 938-938. DOI: 10.1158/1538-7445.Am2013-938  0.416
Show low-probability matches.